METR's TH2 evaluation reveals frontier AI time horizons doubling every 110 days on verifiable code, while autonomous research ...
Python enables geoscientists to analyze and display datasets, with applications including natural hazard and climate ...
Researchers demonstrate that expanding subsplit directed acyclic graphs recovers credible phylogenetic trees, though ...
Recursive, an AI startup founded last year, is starting to live up to its name. The company, which is trying to build AI that can improve itself, released its first model, Flint, on Wednesday. Flint ...
For the past few days I’ve been testing an impressive open-weight AI coding model called Flint. It suggests that fully recursive self-improvement, or RSI—an exciting and controversial approach that ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Exponent demonstrates strong demand recovery, with Q2 revenue before reimbursement up 12% to $148.9M and EBITDA margin rising to 28.7%. I see sustainable growth potential, but hiring discipline and ...
“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...
It's a common occurrence: You have your fully charged laptop plugged in before you, but your smartphone is seriously lagging behind. So, you unplug the charger from your laptop and use it with your ...
Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...
The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...
Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.